Pharmaceutical - Pharmaceutical, Humira


Current filters:


Popular Filters

1 to 25 of 44 results

Approval of Takeda’s Entyvio marks “historic change” for IBD treatment

Approval of Takeda’s Entyvio marks “historic change” for IBD treatment


The recent approval of Japanese drug major Takeda’s Entyvio (vedolizumab) by the European Medicines…

EntyvioGastro-intestinalsHumiraMarkets & MarketingPharmaceuticalRemicadeSimponi InjectionStelaraTakeda Pharmaceutical

AbbVie gains FDA orphan designation for Humira in uveitis


The US Food and Drug Administration granted US drugmaker AbbVie’s blockbuster rheumatoid arthritis…


Janssen’s guselkumab shows significant efficacy in moderate to severe plaque psoriasis


New findings presented for the first time at the 2014 Annual Meeting of the American Academy of Dermatology…

DermatologicalsguselkumabHumiraJanssenJohnson & JohnsonPharmaceuticalResearch

Global ulcerative colitis market to reach $6.6 billion by 2022

Global ulcerative colitis market to reach $6.6 billion by 2022


The global ulcerative colitis market value will increase steadily over the coming years, increasing from…

AbbVieEntyvioGastro-intestinalsGlobalHumiraJohnson & JohnsonMarkets & MarketingPharmaceuticalRemicadeSimponi InjectionTakeda Pharmaceuticals

Modest growth forecast for global Crohn’s disease market

Modest growth forecast for global Crohn’s disease market


The global Crohn’s disease (CD) market value is forecast to show modest growth, climbing from $3.2…

AbbVieBiotechnologyEntyvioGastro-intestinalsGlobalHumiraJohnson & JohnsonMarkets & MarketingPharmaceuticalRemicadeStelara InjectionTakeda Pharmaceuticals

Health Canada clears AbbVie’s Humira for UC

Health Canada clears AbbVie’s Humira for UC


In what is now the eighth indication in Canada for its top-selling drug Humira (adalimumab), US drugmaker…

AbbVieAnti-Arthritics/RheumaticsGastro-intestinalsHumiraNorth AmericaPharmaceuticalRegulation

Accelerated growth for AbbVie’s Humira lifts 3rd-quarter results above expectation

Accelerated growth for AbbVie’s Humira lifts 3rd-quarter results above expectation


Shares of AbbVie were up 2.4% at $49.09 in afternoon trading on the New York Stock Exchange on Friday,…


Enbrel and Humira remain the mainstay for first-line biologic rheumatoid arthritis treatment in USA


The vast majority of patients in the USA treated with Amgen's (Nasdaq: AMGN) Enbrel (etanercept) and…

AbbVieAmgenAnti-Arthritics/RheumaticsEnbrelHumiraMarkets & MarketingNorth AmericaPfizerPharmaceuticalXeljanz

German pharma watch dog finds benefits for biologicals in RA


The German Institute for Quality and Efficiency in Health Care (IQWiG) examined nine biotechnologically…

Anti-Arthritics/RheumaticsBiotechnologyCimziaEnbrelEuropeHumiraKineretMabTheraOrenciaPharmaceuticalPricingRegulationRemicadeRoActemraSimponi Injection

Health Canada backs pediatric Humira for Crohn's


US drugmaker AbbVie (NYSE: ABBV) says that Health Canada has approved its blockbuster rheumatoid arthritis…

AbbVieBiotechnologyGastro-intestinalsHumiraNorth AmericaPharmaceuticalRegulation

AbbVie beats expectations, as Humira keeps growing


US drugmaker AbbVie (NYSE: ABBV), spun-out from Abbott Laboratories from the start of this year, reported…


Novartis' secukinumab demonstrates superiority to rival Enbrel in psoriasis study


Swiss drug major Novartis (NOVN: VX) has announced results from a Phase III psoriasis study which showed…

AbbVieAmgenDermatologicalsEnbrelHumiraJanssen BiotechNovartisPharmaceuticalsecukinumabStelara Injectiontofacitinib

EULAR highlights: Celgene's apremilast; AbbVie's Humira; and Lilly's baricitinib


Among highlights of the ongoing European League Against Rheumatism (EULAR) in Madrid, Spain, US biotech…

AbbVieAnti-Arthritics/RheumaticsapremilastbaricitinibBiotechnologyCelgeneEli LillyHumiramethotrexatePharmaceuticalResearch

Bristol-Myers Orencia equals Humira in head-to-head AMPLE RA study


US drug major Bristol-Myers Squibb (NYSE: BMY) has announced the results of year two data from AMPLE…

AbbVieAnti-Arthritics/RheumaticsBristol-Myers SquibbHumiraOrenciaPharmaceuticalResearch

AbbVie/Eisai's Humira has best clinical profile among psoriatic arthritis treatments


Based on clinical data and the opinions of interviewed thought leaders interviewed by health care advisory…

AbbVieAnti-Arthritics/RheumaticsAstellas PharmaBiotechnologyCimziaEisaiEuropeHumiraMarkets & MarketingNorth AmericaPharmaceuticalUCB

Sales of psoriasis drugs to be worth $7.4 billion by 2020


The psoriasis market experienced approximately 36.5 million prevalent cases across the USA, France, Germany,…

AbbVieAmgenAsia-PacificDermatologicalsEnbrelEuropeHumiraJohnson & JohnsonMarkets & MarketingNorth AmericaNovartisPfizerPharmaceuticalsecukinumabStelara Injectiontofacitinib

AbbVie's Humira cleared in EU for polyarticular juvenile idiopathic arthritis


The European Commission has approved an extension of the European Union marketing authorization for US…


Roche's RoActemra shows superiority to Humira in rheumatoid arthritis


Over 50% of rheumatoid arthritis patients can achieve low disease activity or remission with Swiss drug…


US gastroenterologists increasingly using biologics to treat Crohn's patients in remission


Although there have been no significant changes with regard to biologic treatment and Crohn's disease…

AbbVieBiotechnologyCimziaGastro-intestinalsHumiraJanssenMarkets & MarketingNorth AmericaPharmaceuticalRemicadeUCB

1 to 25 of 44 results

Back to top